SEC Filing Summary
Issuer and period: The supplied filing is Celsion Corporation’s unaudited Form 10-Q for the quarter ended June 30, 2018, filed August 14, 2018. Although the request metadata names Imunon, the filing identifies the issuer as Celsion Corporation (ticker CLSN at the time).
Business context
Celsion was a development-stage oncology drug company with no significant product revenue. Its lead candidate, ThermoDox, was in Phase III development for primary liver cancer; GEN-1 was being developed for ovarian and brain cancers. Reported revenue was licensing revenue from a Hisun agreement.
Financial results and liquidity
| Metric | Three months ended June 30, 2018 | Six months ended June 30, 2018 | Comparable 2017 period |
|---|---|---|---|
| Licensing revenue | $125,000 | $250,000 | $125,000 and $250,000, respectively |
| Research and development expense | $4.6 million | $7.3 million | $3.0 million and $6.5 million |
| General and administrative expense | $3.5 million | $5.2 million | $1.6 million and $3.1 million |
| Net loss | $8.2 million | $12.7 million | $4.9 million and $10.1 million |
| Net loss per share, basic and diluted | $0.46 | $0.73 | $0.79 and $1.75 |
| Cash used in operating activities | $8.8 million for six months | $7.3 million for six months |
At June 30, 2018, cash and cash equivalents were $12.8 million; available-for-sale investments were $13.4 million; and accrued investment interest was $56,832. Management reported approximately $26.3 million in these resources, working capital of $20.1 million, and an accumulated deficit of $274.5 million. Total assets were $49.5 million, total liabilities $30.4 million, and stockholders’ equity $19.1 million. The filing does not present a meaningful operating margin for this development-stage business.
Changes from the prior comparable period
Second-quarter operating expenses increased 73% year over year, while first-half expenses increased 30%. Management attributed the increases mainly to higher clinical and research costs, increased compensation and stock-based compensation. First-half stock-based compensation was $3.4 million, versus $0.8 million in 2017. Cash used in operations also increased. Net loss widened, partly offset by higher investment income and, in the 2017 comparison, the absence of a $0.35 million deemed dividend in 2018.
Cash and investments rose from approximately $24.2 million at December 31, 2017 to approximately $26.3 million at June 30, 2018. The company drew $10 million under a new Horizon loan and received $1.3 million net from ATM share sales during the first half. The balance sheet showed $9.2 million of non-current notes payable, net of debt discounts; the loan’s original principal was $10 million.
Outlook, developments and risks
- Management believed available cash and investments would fund operations into the first half of 2020, but said additional funding would be needed to continue development and operations. Approximately $12.2 million remained available under the Cantor ATM facility.
- The company applied to New Jersey’s technology-business tax-loss sale program, seeking approval to sell up to $12.5 million in cumulative state net operating losses. It expected a decision in Q3 2018 and estimated net proceeds of about 90% of the authorized amount; proceeds were not yet assured.
- The Horizon loan bears interest at one-month LIBOR plus 7.625%, is interest-only for 24 months, then amortizes over 24 months. It is secured by a first-priority interest in substantially all company assets other than intellectual property and includes covenants and default provisions.
- The OPTIMA Phase III study’s independent monitoring committee recommended continuing to the final readout after reviewing safety, data integrity and the first 75% of patients randomized. This was not a finding of efficacy. The prior Phase III HEAT study failed its primary progression-free-survival endpoint; cited favorable survival analyses were post hoc subgroup analyses and require caution.
- The company reported promising early OVATION GEN-1 results but the study was small and early-stage. The planned OVATION II program was designed to include a Phase I dose-escalation phase and a randomized Phase II study.
- Key risks include continued losses and financing needs; possible dilution or asset/right concessions; clinical-trial, regulatory, manufacturing and third-party execution risks; and the possibility that candidates fail to demonstrate safety or efficacy. Earn-out liability from the EGEN acquisition was $13.1 million at quarter-end, with changes in fair value recorded as non-cash expense. No legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer and security: this is a 2018 Celsion Corporation filing, notwithstanding the Imunon metadata.
- Track actual cash burn, financing availability and whether the stated runway or expected New Jersey tax-loss proceeds materialized.
- Review Horizon loan terms, collateral, covenants, repayment schedule and interest-rate exposure.
- Check subsequent OPTIMA trial results and distinguish the ongoing pivotal study from retrospective HEAT subgroup findings.
- Assess share dilution from ATM sales, outstanding warrants and equity awards; common shares outstanding were approximately 17.75 million at June 30, 2018.